SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Pink who wrote (949)12/24/1997 6:31:00 AM
From: Pancho Villa  Respond to of 1359
 
Mr. Pink: >>Isn't anyone nervous about the possibility that IPIC could get sued into bankruptcy by former users of dex-fenfluramine, if enough of said users can prove in court that said drug caused damage to their heart-valves?<<

Read my posts starting some time in late September/late October. This is an extremelly dangerous puppy [as per your observations] but people who promote the stock would like you to believe otherwise.

Pancho

PS: be aware that I am short IPIC



To: Mr. Pink who wrote (949)12/24/1997 10:49:00 AM
From: Scott Pratho  Read Replies (1) | Respond to of 1359
 
Redux has been taken by ~10 million patients for over a decade in Europe. It was only on the market for 14 months here. Right now, I think it's more media hype. We'll see what the data shows.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News